Everolimus Cumulative Dose and Dose Intensity in Pancreatic Neuroendocrine Tumors

被引：0
|
作者：
Berardi, R. [1 ]
Torniai, M. [1 ]
Pusceddu, S. [2 ]
Spada, F. [3 ]
Brizzi, M. P. [4 ]
Ibrahim, T. [5 ]
Antonuzzo, L. [6 ]
Ferolla, P. [7 ]
Panzuto, F. [8 ]
Silvestris, N. [9 ]
Partelli, S. [10 ]
Bongiovanni, A. [5 ]
Zichi, C. [4 ]
Riva, N. [5 ]
Rinzivillo, M. [8 ]
机构：
[1] Univ Politecn Marche, Ancona, Italy
[2] INT, Milan, Italy
[3] IEO, Milan, Italy
[4] San Luigi Hosp, Orbassano, Italy
[5] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Meldola, Italy
[6] AOU Careggi, Florence, Italy
[7] Osped S Maria Misericordia, Perugia, Italy
[8] Sapienza Univ Rome, St Andrea Hosp, Sch Med, Rome, Italy
[9] Cancer Inst Giovanni Paolo II, Bari, Italy
[10] Univ Vita & Salute, Osped San Raffaele IRCCS, Milan, Italy
来源：
NEUROENDOCRINOLOGY | 2016年 / 103卷
关键词：
PNET; Dose intensity; Targeted therapy; Everolimus; Cumulative dose;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
L2
引用
收藏
页码：77 / 77
页数：1
相关论文
共 50 条
  • [31] A Study on the Safety and Effectiveness of Everolimus in Liver Transplant Recipients for Pancreatic Neuroendocrine Tumors.
    Zhao, Xu
    Vanatta, Jason
    Eason, James
    AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 : 103 - 103
  • [32] Pneumocystis jirovecii pneumonia under everolimus in two patients with metastatic pancreatic neuroendocrine tumors
    Carbonnaux, Melodie
    Molin, Yann
    Souquet, Pierre-Jean
    Tantin, Arnaud
    Lombard-Bohas, Catherine
    Walter, Thomas
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (06) : 1308 - 1310
  • [33] Advanced pancreatic Neuroendocrine Tumors: mTOR Inhibitor Afinitor® (Everolimus) receives EU Approval
    不详
    VISZERALMEDIZIN, 2011, 27 (05): : 403 - 403
  • [34] PAK4-NAMPT Dual Inhibition Sensitizes Pancreatic Neuroendocrine Tumors to Everolimus
    Uddin, M.
    Mpilla, G.
    Al-Hallak, M. N.
    Aboukameel, A.
    Li, Y.
    Kim, S.
    Beydoun, R.
    Dyson, G.
    Baloglu, E.
    Senapedis, W.
    Landesman, Y.
    Wagner, K.
    Viola, N.
    El-Rayes, B. F.
    Philip, P. A.
    Mohammad, R.
    Azmi, A. S.
    PANCREAS, 2021, 50 (07) : 1105 - 1105
  • [35] Pneumocystis jirovecii pneumonia under everolimus in two patients with metastatic pancreatic neuroendocrine tumors
    Mélodie Carbonnaux
    Yann Molin
    Pierre-Jean Souquet
    Arnaud Tantin
    Catherine Lombard-Bohas
    Thomas Walter
    Investigational New Drugs, 2014, 32 : 1308 - 1310
  • [36] The Efficacy of Everolimus and Sunitinib in Patients with Sporadic or Germline Mutated Metastatic Pancreatic Neuroendocrine Tumors
    Nunez, J. E.
    Donadio, M.
    Rocha Filho, D.
    Rego, J.
    Barros, M.
    Formiga, M. N.
    Lopez, R.
    Riechelmann, R.
    NEUROENDOCRINOLOGY, 2019, 108 : 176 - 176
  • [37] Everolimus and sunitinib for advanced pancreatic neuroendocrine tumors: A matching-adjusted indirect comparison
    Signorovitch J.
    Swallow E.
    Kantor E.
    Wang X.
    Klimovsky J.
    Haas T.
    Devine B.
    Metrakos P.
    Experimental Hematology & Oncology, 2 (1)
  • [38] PAK4-NAMPT Dual Inhibition Sensitizes Pancreatic Neuroendocrine Tumors to Everolimus
    Mpilla, Gabriel B.
    Uddin, Md Hafiz
    Al-Hallak, Mohammed N.
    Aboukameel, Amro
    Li, Yiwei
    Kim, Steve H.
    Beydoun, Rafic
    Dyson, Gregory
    Baloglu, Erkan
    Senapedis, William T.
    Landesman, Yosef
    Wagner, Kay-Uwe
    Viola, Nerissa T.
    El-Rayes, Bassel F.
    Philip, Philip A.
    Mohammad, Ramzi M.
    Azmi, Asfar S.
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (10) : 1836 - 1845
  • [39] PRRT of neuroendocrine tumors: individualized dosimetry or fixed dose scheme?
    Haug, Alexander R.
    EJNMMI RESEARCH, 2020, 10 (01)
  • [40] High-Dose Treatment with Somatostatin Analogs in Neuroendocrine Tumors
    Modica, R.
    Ramundo, V
    Marciello, F.
    Marotta, V
    Pizza, G.
    Carratu, A. C.
    di Roseto, De Luca C.
    Buonomano, P.
    Giordano, C.
    Trimarchi, F.
    Colao, A.
    Faggiano, A.
    NEUROENDOCRINOLOGY, 2015, 102 (1-2) : 125 - 125
12345